1868 |
Streptococcus pyogen
es
|
Sarcoma |
First use of bacteria in cancer treatment |
[20] |
1891 |
Streptococcus pyogen
es
|
Malignant sarcoma |
Coley’s toxins |
[21] |
1989 |
Mycobacterium bovis
|
Bladder cancer |
Bacillus Calmette–Guerin vaccine (BCG) approved by the FDA |
[22] |
2000 |
Salmonella typhimurium VNP20009
|
Solid tumor |
Deletion of the purI and msbB genes which reduce the virulence and the risk of septic shock |
[23] |
2005 |
Clostridium novyi-NT |
HCT116 colorectal cancer |
Combination of bacterial therapy and traditional drug therapy |
[24] |
2006 |
Escherichia coli
|
HeLa, HepG2, and U2OS cell lines |
Characterization of invasin from Yersinia pseudotuberculosis as an output module |
[25] |
2011 |
Salmonella Typhimurium SL7207 |
Colorectal carcinoma |
Engineered to survive only in anaerobic conditions without otherwise affecting its functions |
[26] |